|
Session 107
Poster Abstracts
Outcomes on ART in Resource-constrained Settings: Randomized Trials and Observational Cohorts
Wednesday, 1-2:30 pm
Poster Hall |
594
 |
Phidisa II: A Randomized 2x2 Factorial Trial Comparing Initial Therapy of Efavirenz with Lopinavir/Ritonavir and Zidovudine + Didanosine with Stavudine + Lamivudine in Treatment-naïve HIV-infected Persons with < 200 CD4+ Cells/mm3 or a Prior AIDS Diagnosis
Andrew Ratsela*1, M Polis2, and the Phidisa II Study Group
1South African Military Hlth Svc, South African Natl Defense Forces, Pretoria and 2NIAID, NIH, Bethesda, MD, US |
595
|
NNRTI Outcomes among HIV-1C-infected Adults Receiving First-line HAART in Botswana: Results from a Randomized Clinical Trial
William Wester*1,2, H Bussman2,3, A Thomas3, V Degruttola3,4, O Okezie2, S Moyo2, M Mine5, J Makhema2, M Essex2,3, and R Marlink2,3
1Vanderbilt Univ Sch of Med, Nashville, TN, US; 2Botswana-Harvard AIDS Inst Partnership; 3Harvard Sch of Publ Hlth, Boston, MA, US; 4Harvard Statistical Data Analysis Ctr, Boston, MA, US; and 5Ministry of Hlth, Botswana |
| 596a |
AIDS as a Chronic Disease in Africa: A 10-Year Follow-up of Patients under ART in Senegal
Papa Salif Sow*1, P Debaudrap2, J Etard2, A Diouf1, N Ngom Gueye1, A Dieng1, P Gueye3, B Ndiaye4, N Toure Kane5, E Delaporte2, and ANRS 1215/ISAARV
1Dept Infect Dis Univ Dakar; 2IRD U 145 Montpellier France; 3Hop Principal Dakar; 4Pharm CHU Fann; and 5Labo Bacterio-Virol Le Dantec Dakar |
| 596b |
When to Start ART—A Policy Evaluation While Awaiting Trial Results: South Africa
Rochelle Walensky*1,2,3, L Wolf2, R Wood4, M Fofana2, K Freedberg1,2,5,6, N Martinson7,8, D Paltiel9, X Anglaret10, M Weinstein5, and E Losina1,3,11,12
1Harvard Univ Ctr for AIDS Res, Harvard Med Sch, Boston, MA, US; 2Massachusetts Gen Hosp, Boston, US; 3Brigham and Women`s Hosp, Boston, MA, US; 4Desmond Tutu HIV Ctr, Inst of Infectious Diseases and Molecular Med, Univ of Cape Town, South Africa; 5Harvard Sch of Publ Hlth, Boston, MA, US; 6Boston Univ Sch of Publ Hlth, MA, US; 7Johns Hopkins Univ Sch of Med, Baltimore, MD, US; 8Univ of the Witwatersrand, Johannesburg, South Africa; 9Yale Univ Sch of Med, New Haven, CT, US; 10Univ Victor Segalen Bordeaux 2, France; 11Massachusetts Gen Hosp, Boston, US; and 12Boston Univ Sch of Publ Hlth, MA, US |
597
|
HIV RNA Levels 6 Months after ART Initiation Is a Strong, Independent Predictor of Subsequent Survival in HIV-infected Individuals in Sub-Saharan Africa
M Marazzi1, Andrea De Luca*2, E Buonomo3, M Magnano S Lio4, P Narciso5, S Ceffa4, M Bartolo6, I Zimba Da Vitoria7, L Palombi3, and DREAM Study Group
1LUMSA Univ, Rome, Italy; 2Catholic Univ, Rome, Italy; 3Univ of Tor Vergata, Rome, Italy; 4DREAM program, Rome, Italy; 5National Institute for Infectious Diseases "L. Spallanzani", Rome, Italy; 6S Giovanni Addolorata Hospital, Rome, Italy; and 7DREAM Program Coordination, Maputo, Mozambique |
| 598 |
More Advanced Disease at ART Initiation and High Death Rate from Opportunistic Infections Explain Higher Mortality among African Patients Initiating ART in Uganda Compared with London
Philippa Easterbrook*1,2, F Ibrahim1, A Kiragga2, B Castelnuovo2, A Kambugu2, and M Kamya2
1King`s Coll London, UK and 2Infectious Disease Inst, Kampala, Uganda |
599
|
Clinical and Immunological Outcomes among Patients Older than 55 Years Receiving ART in South Africa
Mhairi Maskew*1,2, M Fox3,4, P MacPhail2, and I Sanne1,2
1Right to Care, Johannesburg, South Africa; 2Univ of the Witwatersrand, Johannesburg, South Africa; 3Ctr for Intl Hlth and Devt, Boston Univ, MA, US; and 4Hlth Economics Res Office, Johannesburg, South Africa |
600
|
Lymphocyte T CD4+ Response to ART According to the HIV Type in a Large Cohort Collaboration in West Africa
J Drylewicz1, S Eholie2, M Maiga3, C Amani-Bosse4, P Sow5, D Ekouevi1,6, K Peterson7, E Bissagnene2, F Dabis1, Rodolphe Thiébaut*1, and IeDEA West Africa Collaboration
1INSERM U897 Epidemiology and Biostatistics, Bordeaux, France; 2Service de Maladies Infectieuses et Tropicales (SMIT), CHU de Treichville, Abidjan, Côte d`Ivoire; 3Service d`Hépato-Gastro-Entérologie, Hôpital Gabriel Touré, Bamako, Mali; 4ACONDA - MTCT+ initiative, Abidjan, Côte d`Ivoire; 5ANRS 1215 Cohort, Dakar, Sénégal; 6Programme PAC-CI, CHU de Treichville, Abidjan, Côte d`Ivoire; and 7Fajara Cohort, MRC, Banjul, Gambia |
| 601 |
AIDS-defining Illnesses after Initiating Generic HAART in South India: The Case for Earlier Identification and Intervention
Nagalingeswaran Kumarasamy*1, K Venkatesh2, B Devaleenol1, S Poongulali1, T Yepthomi1, S Saghayam1, R Schooley3, S Solomon1, K Mayer2, and C Benson3
1YR Gaitonde Ctr for AIDS Res and Ed, Chennai, India; 2Warren Alpert Med Sch, Miriam Hosp, Brown Univ, Providence, RI, US; and 3Univ of California, San Diego, US |
602
|
Immune Reconstitution Inflammatory Syndrome Is an Important Contributor to HIV-related Morbidity and Mortality in an ART Program in South Africa
Lewis Haddow*1, Y Moosa2, A Mosam2, N Khanyile2, and P Easterbrook1
1King`s Coll London, UK and 2Univ of KwaZulu-Natal, Durban, South Africa |
603
|
Nevirapine-induced Hepatotoxicity: Incidence, Determinants, and Associated Mortality in a Primary Care ART Program: South Africa
K Chu1,2, A Boulle3, N Ford1, K Hilderbrand1, E Goemaere1, M Abrahams1, S Mathee4, and Gilles Van Cutsem*1
1Medecins sans Frontieres, Cape Town, South Africa; 2Johns Hopkins Univ, Baltimore, MD, US; 3Univ of Cape Town, South Africa; and 4Provincial Govt of the Western Cape, Cape Town, South Africa |
| 604 |
Frequent Occurrence of Virologic Re-suppression without Change in Therapy after High-level Virologic Rebound in Africa
Elvin Geng*1, N Emenyonu2, P Hunt1, M Bwana3, N Musinguzi3, J Bennett1, H Cao1, S Deeks1, J Martin1, and D Bangsberg2
1Univ of California, San Francisco, US; 2Harvard Univ, Boston, MA, US; and 3Mbarara Univ of Sci and Tech, Uganda |
|
